What's new
By:
Filters
Cystic Fibrosis Forum (EXP)

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

A LouLou update

B

beleache

New member
Excellent news Lauren !! Take care & God Bless you guys <img src="i/expressions/heart.gif" border="0"> joni
 
B

beleache

New member
Excellent news Lauren !! Take care & God Bless you guys <img src="i/expressions/heart.gif" border="0"> joni
 
B

beleache

New member
Excellent news Lauren !! Take care & God Bless you guys <img src="i/expressions/heart.gif" border="0"> joni
 
B

beleache

New member
Excellent news Lauren !! Take care & God Bless you guys <img src="i/expressions/heart.gif" border="0"> joni
 
B

beleache

New member
Excellent news Lauren !! Take care & God Bless you guys <img src="i/expressions/heart.gif" border="0"> joni
 
M

mamaScarlett

Active member
i'm so happy to hear that you got in that study, lauren.
you are so committed and as amy said, its a great example for us all.
i know you will stay healthy.
as always, you are in my prayers and thoughts!
 
M

mamaScarlett

Active member
i'm so happy to hear that you got in that study, lauren.
you are so committed and as amy said, its a great example for us all.
i know you will stay healthy.
as always, you are in my prayers and thoughts!
 
M

mamaScarlett

Active member
i'm so happy to hear that you got in that study, lauren.
you are so committed and as amy said, its a great example for us all.
i know you will stay healthy.
as always, you are in my prayers and thoughts!
 
M

mamaScarlett

Active member
i'm so happy to hear that you got in that study, lauren.
you are so committed and as amy said, its a great example for us all.
i know you will stay healthy.
as always, you are in my prayers and thoughts!
 
M

mamaScarlett

Active member
i'm so happy to hear that you got in that study, lauren.
<br />you are so committed and as amy said, its a great example for us all.
<br />i know you will stay healthy.
<br />as always, you are in my prayers and thoughts!
 
C

Cerulean

New member
I am reading up on the Vertex studies atm. Could anyone explain to me or send me a link as to why researchers have focused on the G551D mutation and not the more common DF508 mutation. It just seems a bit counterintuitive.<img src="i/expressions/face-icon-small-confused.gif" border="0">

BTW A big ole GRATS to you for getting in and participating in the study. Your heroic efforts will benefit us all! <img src="i/expressions/face-icon-small-happy.gif" border="0">
 
C

Cerulean

New member
I am reading up on the Vertex studies atm. Could anyone explain to me or send me a link as to why researchers have focused on the G551D mutation and not the more common DF508 mutation. It just seems a bit counterintuitive.<img src="i/expressions/face-icon-small-confused.gif" border="0">

BTW A big ole GRATS to you for getting in and participating in the study. Your heroic efforts will benefit us all! <img src="i/expressions/face-icon-small-happy.gif" border="0">
 
C

Cerulean

New member
I am reading up on the Vertex studies atm. Could anyone explain to me or send me a link as to why researchers have focused on the G551D mutation and not the more common DF508 mutation. It just seems a bit counterintuitive.<img src="i/expressions/face-icon-small-confused.gif" border="0">

BTW A big ole GRATS to you for getting in and participating in the study. Your heroic efforts will benefit us all! <img src="i/expressions/face-icon-small-happy.gif" border="0">
 
C

Cerulean

New member
I am reading up on the Vertex studies atm. Could anyone explain to me or send me a link as to why researchers have focused on the G551D mutation and not the more common DF508 mutation. It just seems a bit counterintuitive.<img src="i/expressions/face-icon-small-confused.gif" border="0">

BTW A big ole GRATS to you for getting in and participating in the study. Your heroic efforts will benefit us all! <img src="i/expressions/face-icon-small-happy.gif" border="0">
 
C

Cerulean

New member
I am reading up on the Vertex studies atm. Could anyone explain to me or send me a link as to why researchers have focused on the G551D mutation and not the more common DF508 mutation. It just seems a bit counterintuitive.<img src="i/expressions/face-icon-small-confused.gif" border="0">
<br />
<br />BTW A big ole GRATS to you for getting in and participating in the study. Your heroic efforts will benefit us all! <img src="i/expressions/face-icon-small-happy.gif" border="0">
 
K

kmaried

New member
I like this link... it answers a lot about the VX-770 and VX-809 drugs & trials.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/index.cfm?dspPrintReady=Y
">http://www.cff.org/research/Cl...x.cfm?dspPrintReady=Y
</a>
If you don't feel like reading, the G551D mutation allows the CFTR protein to get to the cell surface, but not function correctly. VX-770 increases the function of the protein that is already there. The D508 mutation is a little more complicated b/c they don't think much of the protein gets to the cell surface. I will hopefully be participating in the VX-770 trial for dd508 in a few weeks. They will then see if the VX-770 does any good for dd508-ers.

Vertex is developing a 2nd compound VX-809. This compound (I think in phase 2 trials) will help to increase the concentration of proteins on the cell surface. If that works, they'll be able to use VX-770 to get it working correctly.

At least, that is my layman's understanding. It seems like G551D was a bit of an easier goal... so if they can get that to work, they'll try for the more complicated stuff <img src="i/expressions/face-icon-small-wink.gif" border="0">

Thanks, Lauren!... for posting & participating!!
 
K

kmaried

New member
I like this link... it answers a lot about the VX-770 and VX-809 drugs & trials.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/index.cfm?dspPrintReady=Y
">http://www.cff.org/research/Cl...x.cfm?dspPrintReady=Y
</a>
If you don't feel like reading, the G551D mutation allows the CFTR protein to get to the cell surface, but not function correctly. VX-770 increases the function of the protein that is already there. The D508 mutation is a little more complicated b/c they don't think much of the protein gets to the cell surface. I will hopefully be participating in the VX-770 trial for dd508 in a few weeks. They will then see if the VX-770 does any good for dd508-ers.

Vertex is developing a 2nd compound VX-809. This compound (I think in phase 2 trials) will help to increase the concentration of proteins on the cell surface. If that works, they'll be able to use VX-770 to get it working correctly.

At least, that is my layman's understanding. It seems like G551D was a bit of an easier goal... so if they can get that to work, they'll try for the more complicated stuff <img src="i/expressions/face-icon-small-wink.gif" border="0">

Thanks, Lauren!... for posting & participating!!
 
K

kmaried

New member
I like this link... it answers a lot about the VX-770 and VX-809 drugs & trials.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/index.cfm?dspPrintReady=Y
">http://www.cff.org/research/Cl...x.cfm?dspPrintReady=Y
</a>
If you don't feel like reading, the G551D mutation allows the CFTR protein to get to the cell surface, but not function correctly. VX-770 increases the function of the protein that is already there. The D508 mutation is a little more complicated b/c they don't think much of the protein gets to the cell surface. I will hopefully be participating in the VX-770 trial for dd508 in a few weeks. They will then see if the VX-770 does any good for dd508-ers.

Vertex is developing a 2nd compound VX-809. This compound (I think in phase 2 trials) will help to increase the concentration of proteins on the cell surface. If that works, they'll be able to use VX-770 to get it working correctly.

At least, that is my layman's understanding. It seems like G551D was a bit of an easier goal... so if they can get that to work, they'll try for the more complicated stuff <img src="i/expressions/face-icon-small-wink.gif" border="0">

Thanks, Lauren!... for posting & participating!!
 
K

kmaried

New member
I like this link... it answers a lot about the VX-770 and VX-809 drugs & trials.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/index.cfm?dspPrintReady=Y
">http://www.cff.org/research/Cl...x.cfm?dspPrintReady=Y
</a>
If you don't feel like reading, the G551D mutation allows the CFTR protein to get to the cell surface, but not function correctly. VX-770 increases the function of the protein that is already there. The D508 mutation is a little more complicated b/c they don't think much of the protein gets to the cell surface. I will hopefully be participating in the VX-770 trial for dd508 in a few weeks. They will then see if the VX-770 does any good for dd508-ers.

Vertex is developing a 2nd compound VX-809. This compound (I think in phase 2 trials) will help to increase the concentration of proteins on the cell surface. If that works, they'll be able to use VX-770 to get it working correctly.

At least, that is my layman's understanding. It seems like G551D was a bit of an easier goal... so if they can get that to work, they'll try for the more complicated stuff <img src="i/expressions/face-icon-small-wink.gif" border="0">

Thanks, Lauren!... for posting & participating!!
 
K

kmaried

New member
I like this link... it answers a lot about the VX-770 and VX-809 drugs & trials.
<br />
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/index.cfm?dspPrintReady=Y
">http://www.cff.org/research/Cl...x.cfm?dspPrintReady=Y
</a><br />
<br />If you don't feel like reading, the G551D mutation allows the CFTR protein to get to the cell surface, but not function correctly. VX-770 increases the function of the protein that is already there. The D508 mutation is a little more complicated b/c they don't think much of the protein gets to the cell surface. I will hopefully be participating in the VX-770 trial for dd508 in a few weeks. They will then see if the VX-770 does any good for dd508-ers.
<br />
<br />Vertex is developing a 2nd compound VX-809. This compound (I think in phase 2 trials) will help to increase the concentration of proteins on the cell surface. If that works, they'll be able to use VX-770 to get it working correctly.
<br />
<br />At least, that is my layman's understanding. It seems like G551D was a bit of an easier goal... so if they can get that to work, they'll try for the more complicated stuff <img src="i/expressions/face-icon-small-wink.gif" border="0">
<br />
<br />Thanks, Lauren!... for posting & participating!!
 
You must log in or register to reply here.
Top